Novacyt S.A. Director/PDMR Shareholding (3414F)
14 November 2020 - 5:05AM
UK Regulatory
TIDMNCYT
RNS Number : 3414F
Novacyt S.A.
13 November 2020
Novacyt S.A.
("Novacyt" or the "Company")
Director/PDMR Shareholding
Paris, France and Camberley, UK - 13 November 2020 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, announces that it has been notified that, on
13 November 2020, James McCarthy (PDMR), a corporate consultant,
acquired 10,000 ordinary shares of EUR1/15 each in the Company at
an average price of GBP8.953 per share. The resultant beneficial
shareholding of Mr McCarthy is 10,000 ordinary shares representing
0.01% of the Company's issued share capital.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name
James McCarthy
-------------------------------- -------------------------------
2. Reason for the Notification
-----------------------------------------------------------------
a) Position/status Corporate consultant and
classified as a PDMR of the
Company
-------------------------------- -------------------------------
b) Initial notification/ Amendment Initial Notification
-------------------------------- -------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------
a) Name Novacyt S.A.
-------------------------------- -------------------------------
b) LEI 213800BWAC2BF295EG28
-------------------------------- -------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------
a) Description of the Financial ordinary shares of EUR1/15
instrument, type of instrument each
-------------------------------- -------------------------------
Identification code FR0010397232
-------------------------------- -------------------------------
b) Nature of the transaction Acquisition of Ordinary Shares
-------------------------------- -------------------------------
c) Price(s) and volume(s) Price Volume
GBP8.848 1,130
-------
GBP8.931 4,478
-------
GBP9.001 4,320
-------
GBP9.073 72
-------
-------------------------------- -------------------------------
d) Aggregated information: Price Volume
-- Aggregated volume GBP8.953 10,000
-- Price -------
-------------------------------- -------------------------------
e) Date of the transaction
13 November 2020
-------------------------------- -------------------------------
f) Place of the transaction London Stock Exchange, AIM
-------------------------------- -------------------------------
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
Freddie Barnfield / James Black
+44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com ; y.petit@allegrafinance.com
FTI Consulting (International)
Victoria Foster Mitchell / Mary Whittow
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high quality assays
and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGPGMAGUPUGMW
(END) Dow Jones Newswires
November 13, 2020 13:05 ET (18:05 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Apr 2024 to May 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From May 2023 to May 2024